Seeking Alpha·Aug 14, 2026
HeartBeam, Inc. (BEAT) Q2 2026 Earnings Call TranscriptHeartBeam, Inc. (BEAT) Q2 2026 Earnings Call Transcript
HeartBeam remains in a high-risk, pre-revenue developmental stage characterized by consistent quarterly operating losses of approximately $5 million and a rapidly depleting capital base. While the company continues to prioritize R&D, the lack of commercial rev...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$0.10-16.3% vs -$0.09 | $100,000-32.2% vs $147,400 |
Q2 2026 May 13, 2026 | -$0.12+14.3% vs -$0.14 | — vs $149,750 |
Q2 2026 Mar 12, 2026 | -$0.14-7.7% vs -$0.13 | — vs $1M |
Q4 2025 Nov 13, 2025 | -$0.15+6.3% vs -$0.16 | — vs $875,000 |
HeartBeam, Inc. (BEAT) Q2 2026 Earnings Call Transcript
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Second Quarter 2026 Results.
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time.
Healthcare IT is emerging as AI's next growth story as providers adopt AI to cut costs & improve care. Here we present three stocks that are likely to benefit.
Benchmark BEAT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for HeartBeam, Inc. (BEAT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.39 | $21.59M | -0.63 | — | — | -987.32% | — | |
| $29.38 | $79.08M | 1.02 | 12.07% | 17.17% | 136.07% | — | |
| $2.88 | $168.15M | -1.56 | 1057.12% | -1302.78% | -122.85% | — | |
| $522.02 | $41.18B | 39.91 | 10.42% | 25.03% | 71.96% | — | |
| $111.75 | $3.67B | -80.40 | 26.24% | -1.69% | -8.97% | — | |
| $9.20 | $2.45B | -29.68 | 18.96% | -66.74% | -38.36% | — |
HeartBeam, Inc. (BEAT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
HeartBeam, Inc. (BEAT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 14, 2026·SEC
Aug 3, 2026·SEC
Jul 2, 2026·SEC
Get notified when BEAT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
HeartBeam, Inc. (BEAT) stock FAQ — growth, dividends, profitability & financials explained
HeartBeam, Inc. (BEAT) reported a net loss of $20.3M for fiscal year 2025.
HeartBeam, Inc. (BEAT) has a return on equity (ROE) of -987.3%. Negative ROE indicates the company is unprofitable.
HeartBeam, Inc. (BEAT) had negative free cash flow of $14.0M in fiscal year 2025, likely due to heavy capital investments.
